Interaction between Duloxetine and Rivaroxaban
Risque principal : Augmentation du risque hémorragique
- The combination of duloxetine and rivaroxaban increases the risk of bleeding through an additive pharmacodynamic mechanism, requiring close clinical monitoring but not being an absolute contraindication, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 2
Mécanisme d'interaction
- The duloxetine, like all serotonin and norepinephrine reuptake inhibitors (SNRIs), can cause abnormal bleeding by affecting platelet function, with an additive effect to the anticoagulant effect of rivaroxaban 1, 2
- SNRIs interfere with platelet aggregation by decreasing the available serotonin in platelets, which adds to the anticoagulant effect of rivaroxaban 1, 2
Évaluation du risque hémorragique
- Before prescribing this combination, evaluate the following risk factors: renal function, with increased risk if creatinine clearance is less than 50 mL/min 3
- Hepatic function, with duloxetine being contraindicated in cases of hepatic insufficiency 1, 2
- History of bleeding, including gastrointestinal bleeding and previous hemorrhages 3
- Platelet count, with pre-existing thrombocytopenia 3
Recommandations de surveillance
- Monitor for signs of bleeding, including unusual bruising, prolonged bleeding from cuts, black or tarry stools, blood in urine, and gingival bleeding, as recommended by clinical guidelines 6
- Periodic hematological monitoring, including hemoglobin and hematocrit, particularly in high-risk patients 5
Précautions spécifiques
- Patients with moderate renal insufficiency (creatinine clearance 15-49 mL/min) require increased caution as both medications may have altered pharmacokinetics 5
- Patients with unresected tumors or active mucosal lesions are at particularly high risk of bleeding with rivaroxaban 3